Vera Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Vera Therapeutics, Inc. (VERA) reported Increase (Decrease) in Accounts Payable of -$7.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-10
- Vera Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $664.00K, a 82.95% decline year-over-year.
- Vera Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$7.97M, a 598.81% decline year-over-year.
- Vera Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $3.63M, a 18.35% increase year-over-year.
- Vera Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $4.79M.
- Vera Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was $13.91M.
- Vera Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$3.45M.
- Vera Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$873.00K, a 108.23% decline from fiscal 2022.
- Vera Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was $10.61M, a 2132.84% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $664.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$7.30M 10-Q · filed 2026-08-10 | -$3.68M derived: sum of 3 quarters · filed 2026-08-10 | $1.12M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$7.97M 10-Q · filed 2026-05-07 | -$4.34M derived: sum of 2 quarters · filed 2026-05-07 | $452.00K derived: sum of 3 quarters · filed 2026-05-07 | $4.35M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $3.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.42M derived: sum of 2 quarters · filed 2026-02-26 | $12.31M derived: sum of 3 quarters · filed 2026-08-10 | $13.91M 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $8.69M derived: sum of 2 quarters · filed 2026-08-10 | $10.29M 10-Q · filed 2025-11-05 | $13.35M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $3.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $5.49M 10-Q · filed 2026-08-10 | $8.55M derived: sum of 3 quarters · filed 2026-08-10 | $8.49M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.60M 10-Q · filed 2026-05-07 | $4.66M derived: sum of 2 quarters · filed 2026-05-07 | $4.60M derived: sum of 3 quarters · filed 2026-05-07 | $4.05M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.00M derived: sum of 2 quarters · filed 2026-02-26 | $2.46M derived: sum of 3 quarters · filed 2026-02-26 | -$3.45M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$62.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$607.00K derived: sum of 2 quarters · filed 2025-11-05 | -$6.52M 10-Q · filed 2025-11-05 | -$7.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$545.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$6.45M 10-Q · filed 2025-08-05 | -$7.64M derived: sum of 3 quarters · filed 2026-02-26 | -$8.62M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$5.91M 10-Q · filed 2025-05-07 | -$7.09M derived: sum of 2 quarters · filed 2026-02-26 | -$8.07M derived: sum of 3 quarters · filed 2026-02-26 | -$117.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.16M derived: sum of 2 quarters · filed 2026-02-26 | $5.79M derived: sum of 3 quarters · filed 2026-02-26 | -$873.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | -$980.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $6.97M derived: sum of 2 quarters · filed 2024-11-07 | $309.00K 10-Q · filed 2024-11-07 | $5.29M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $7.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.29M 10-Q · filed 2024-08-08 | $6.27M derived: sum of 3 quarters · filed 2024-08-08 | $6.20M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$6.67M 10-Q · filed 2024-05-10 | -$1.69M derived: sum of 2 quarters · filed 2024-05-10 | -$1.76M derived: sum of 3 quarters · filed 2024-05-10 | -$2.00M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $4.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $4.91M derived: sum of 2 quarters · filed 2024-03-27 | $4.66M derived: sum of 3 quarters · filed 2024-03-27 | $10.61M 10-K · filed 2024-03-27 |
| 2022-09-30 | -$72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$316.00K derived: sum of 2 quarters · filed 2023-11-09 | $5.63M 10-Q · filed 2023-11-09 | $6.05M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$244.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $5.70M 10-Q · filed 2023-08-10 | $6.12M derived: sum of 3 quarters · filed 2023-08-10 | $5.36M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $5.94M 10-Q · filed 2023-05-11 | $6.36M derived: sum of 2 quarters · filed 2023-05-11 | $5.60M derived: sum of 3 quarters · filed 2023-05-11 | $6.62M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $420.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$339.00K derived: sum of 2 quarters · filed 2023-03-28 | $673.00K derived: sum of 3 quarters · filed 2023-03-28 | $475.00K 10-K · filed 2023-03-28 |
| 2021-09-30 | -$759.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $253.00K derived: sum of 2 quarters · filed 2022-11-09 | $55.00K 10-Q · filed 2022-11-09 | $625.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $814.00K 10-Q · filed 2022-08-10 | $1.38M derived: sum of 3 quarters · filed 2022-08-10 | $995.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$198.00K 10-Q · filed 2022-05-16 | $372.00K derived: sum of 2 quarters · filed 2022-05-16 | -$17.00K derived: sum of 3 quarters · filed 2022-05-16 | $366.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $570.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $181.00K derived: sum of 2 quarters · filed 2022-03-28 | $564.00K derived: sum of 3 quarters · filed 2022-03-28 | $567.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | -$389.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$6.00K derived: sum of 2 quarters · filed 2021-11-10 | -$3.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $383.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $386.00K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $3.00K 10-Q · filed 2021-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |